PNPLA3 and TM6SF2 polymorphisms in Brazilian patients with nonalcoholic fatty liver disease

Table 1 Clinical and demographic characteristics of nonalcoholic fatty liver disease patients and controls

Variables	NAFLD, n = 148	Controls, n = 137	P value
Female	111 (75.0%)	97 (70.8%)	0.426
Age (yr)	57 (46.3-63)	55 (43 61.5)	0.610
BMI (kg/m2)	32.8 ± 4.8	25.4 ± 3.3	< 0.0001
Hypertension	98 (66.2%)	24 (17.5%)	< 0.0001
Diabetes mellitus	69 (46.6%)	12 (8.8%)	< 0.0001
Dyslipidemia	108 (73.0%)	19 (13.5%)	< 0.0001
Fasting glucose (mg/dL)	101 (90-124.8)	88 (83-98)	< 0.0001
AST (U/L)	34 (25.5-56.5)	24 (20.3-29)	< 0.0001
ALT (U/L)	38 (28-70.5)	29.5 (23-38)	< 0.0001
GGT (U/L)	53 (29-116)	28 (18.5-55.5)	< 0.0001
ALP (U/L)	97 (74-116.8)	75 (58.3-83.8)	< 0.0001
Total bilirubin (mg/dL)	0.6 (0.5-0.9)	0.7 (0.5-0.8)	0.438
Triglycerides (mg/dL)	162.5 (110-205.3)	126.5 (93-176)	0.006
Total cholesterol (mg/dL)	195.8 ± 41.5	179.9 ± 47.1	0.006
VLDL (mg/dL)	32 (22-42.3)	24.5 (17.3-33.8)	0.001
HDL (mg/dL)	48 (39.5-54)	47 (40.5-60.8)	0.404
LDL (mg/dL)	107.5 (89.5-137.9)	96 (67.8-117.5)	0.009
Platelets (109/L)	219.4 ± 81.8	254.6 ± 82.4	0.439
Ferritin (ng/mL)	89 (42.7-168.5)	32 (32-32)	0.349
D vitamin (ng/mL)	22 (19-27.7)	26.95 (20.5-32.5)	0.139

The data are expressed as n (%), or as mean ± SD for normally distributed variables and as median (interquartile range) when distribution of the variable was skewed. NAFLD: Nonalcoholic fatty liver disease; BMI: Body mass index; AST: Serum aspartate aminotransferase; VLDL: Very low-density lipoprotein; ALT: Alanine aminotransferase; ALP: Alkaline phosphatase; LDL: Low-density lipoprotein cholesterol.